Herceptin sBLA (correction)
Executive Summary
Roche/Genentech submitted a supplemental BLA for Herceptin for adjuvant treatment of early stage HER2-positive breast cancer in the first quarter and plan to file an sBLA for HER2-positive advanced gastric cancer in 2008; "The Pink Sheet" incorrectly reported that trastuzumabwas also under review for first-line, non-squamous non-small cell lung cancer (1"The Pink Sheet" June 26, 2006, p. 17). The firms' Avastin has an sBLA pending for that use...